Editas Medicine, EDIT-401, gene editing, hyperlipidemia, familial hypercholesterolemia, HeFH, LDL-C, LDLR, Phase 1/2 clinical trial, Strive trial, AHA Scientific Sessions

CAMBRIDGE, Mass. — October 8, 2026 Editas Medicine, Inc. announced approval to initiate its Phase 1/2 Strive clinical trial...